ReviewFrontiers in neuroscience2021
Adenosine A
Review in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Working Memory Impairment Induced by Chemotherapy-A Narrative Review.Brain sciences · 2026Review
- From Serum to Genome: γ-Glutamyltransferase Gene Family Variants Shape Ischemic Stroke Risk via Sex-Specific Gene-Environment Interactions.Life (Basel, Switzerland) · 2026Article
- Caffeine and human performance: from molecular mechanisms to exercise and recovery.Frontiers in physiology · 2026Review
- Dual CD73/AFrontiers in pharmacology · 2026Article
- Upregulation of adenosine AMolecular psychiatry · 2025Article
- Adenosine ANeuropharmacology · 2025Article
- Review
- Macamides as Potential Therapeutic Agents in Neurological Disorders.Neurology international · 2024Review
- Effect of curcumin-donepezil combination on spatial memory, astrocyte activation, and cholinesterase expressions in brain of scopolamine-treated rats.Molecular biology reports · 2024Article
- Adenosine signaling: a potential therapeutic target for psychogenic erectile dysfunction.American journal of translational research · 2024Review
- Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor.PloS one · 2024Article
- Anti-inflammatory potency of novel ecto-5'-nucleotidase/CD73 inhibitors in astrocyte culture model of neuroinflammation.European journal of pharmacology · 2023Article
- Adenosine ABiomolecules · 2023Article
- Lateral septum adenosine ANature communications · 2023Article
- Association of the ADORA2A receptor and CD73 polymorphisms with epilepsy.Frontiers in pharmacology · 2023Article
- Astrocyte regulation of synaptic signaling in psychiatric disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Review
- Article
- Pathophysiological Role and Medicinal Chemistry of AMolecules (Basel, Switzerland) · 2022Review
- ACurrent medicinal chemistry · 2022Review
- Molecular mechanisms for the prevention and promoting the recovery from ischemic stroke by nutraceutical laminarin: A comparative transcriptomic approach.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular adenosine is produced with increased metabolic activity or stress, acting as a paracrine signal of cellular effort. Adenosine receptors are most abundant in the brain, where adenosine acts through inhibitory A
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.